Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

NCT05489523 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Transthyretin Cardiac Amyloidosis

Interventions

DRUG: Tafamidis 61 MG

Sponsor

University of Texas Southwestern Medical Center